Non-peptide Inhibitors of Proprotein Convertase Subtilisin Kexins (PCSKs)

Non-peptide Inhibitors of Proprotein Convertase Subtilisin Kexins (PCSKs)

An Overall Review of Existing and New Data

Utpal Chandra De, Priyambada Mishra, Prasenjit Rudra Pal
ISBN: 9781615044740 | PDF ISBN: 9781615044757
Copyright © 2012 | 76 Pages | Publication Date: 09/01/2012

BEFORE YOU ORDER: You may have Academic or Corporate access to this title. Click here to find out: 10.4199/C00066ED1V01Y201209PAC003

Ordering Options: Paperback $40.00   E-book $32.00   Paperback & E-book Combo $50.00

Why pay full price? Members receive 15% off all orders.
Learn More Here

Read Our Digital Content License Agreement (pop-up)

Purchasing Options:

The Ca+2-dependent mammalian Proprotein Convertase Subtilisin Kexins (PCSKs) or Proprotein/ Prohormone Convertases (PCs) are a family of endoproteases that play critical roles not only in normal development and metabolism but also in various physiological and pathological conditions. These were initiated by the proteolytic processing of large inactive proproteins into their shorter bioactive mature forms by the PCSK enzymes. These events take place in a highly selective, orchestrated, and stepwise manner. Among the various proprotein substrates of PCSK enzymes, particularly important are the precursor growth factors that include proPDGF-A, B, proIGF-1, 2 and proVEGF-C because of their strong implications in neoplasia initiation, progression, and metastasis. As a result of these findings, PCSK enzymes, particularly furin or PCSK3, became a major target for possible interventions of cancer via the use of their selective inhibitors. Significant progress has been accomplished in the development of peptide and protein-based PCSK inhibitors. However, non-peptide PCSK9 inhibitors are more preferable because of their drug-like and other characteristics. So far, a few non-peptide inhibitors of PCSK enzymes of various types of chemical structures have been described in the literature. These include (i) Carbocyclic compounds of diterpene and streptamine class. (ii) Nitrogen (N)-based heterocyclic compounds of various types and chemical structures such as (a) pyrrolidine bis piperazines, (b) Cu/Zn chelating terpyridine derivatives; (iii) Oxygen (O)-based Heterocyclic compounds of varying types of chemical structures such as (a) Flavonoids, (b) Coumarins of simple and dimeric types, (c) Quinonoids, (d) Iridoids; (iv) Aromatic compounds such as (a) Aryl guanidino and amidino derivatives, (b) Naphthyl fluorescein derivative, and (c) Phenyl Arsonic acids; and (v) C2-symmetrical aromatic azo-compounds. When measured against a small peptidyl-MCA fluorogenic substrate, these inhibitors displayed IC50 values ranging from nM to ?M. A number of these inhibitors exhibited significant anti-PCSK activity when tested in ex vivo or cell culture conditions. This article provides an overall review of all non-peptide PCSK inhibitors so far reported in the literature along with those we identified recently for the first time and not yet published. The potential implications of these molecules as biochemical, therapeutical, or clinical agents will also be discussed.

Table of Contents

Historical Perspectives
Class of PCSK Inhibitors
Comparative Analyses of Peptide and Non-peptide Inhibitors
Class of Non-peptide Inhibitors of PCSKs
Comparison of Activities of Non-peptide Inhibitors of PCSK Enzymes
Blockade of Proprotein Processing by Non-peptide PCSK Inhibitors in Cellular Models
Animal Study with Non-peptide PCSK Inhibitors
Future Perspectives of Non-peptide PCSK Inhibitors and Concluding Remarks

About the Author(s)

Utpal Chandra De, Department of Medicine, Biochemistry, Microbiology and Immunology, University of Ottawa, Canada

Priyambada Mishra, Department of Medicine, Biochemistry, Microbiology and Immunology, University of Ottawa, Canada

Prasenjit Rudra Pal, Department of Chemistry, Tripura University, India

Browse by Subject
Case Studies in Engineering
ACM Books
SEM Books
0 items

Note: Registered customers go to: Your Account to subscribe.

E-Mail Address:

Your Name: